Emcure becomes first Indian company to commercialise semaglutide 2.4 mg, the second brand of Wegovy®, in India. Previous Post Mahesh Patil says market returns to mirror earnings, sees 10-14% upside Next Post Bajaj Finance Q2 Results: Stock at 52-week high ahead of earnings; FY26 guidance in focus Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
